| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:TQ05310
CAS:2071196-10-4
Package:10mg;50mg
|
|
| | TQ05310 Basic information |
| Product Name: | TQ05310 | | Synonyms: | TQ05310;1,3,5-Triazine-2,4-diamine, N2-(1,1-dimethylethoxy)-N4-[2-(trifluoromethyl)-4-pyridinyl]-6-[6-(trifluoromethyl)-2-pyridinyl]- | | CAS: | 2071196-10-4 | | MF: | C19H17F6N7O | | MW: | 473.38 | | EINECS: | | | Product Categories: | | | Mol File: | 2071196-10-4.mol |  |
| | TQ05310 Chemical Properties |
| Boiling point | 468.779±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.466±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 2.573±0.26(predicted) |
| | TQ05310 Usage And Synthesis |
| Uses | TQ05310 is an orally available inhibitor of IDH2 mutants, targeting both IDH2-R140Q (IC50=136.9 nM) and IDH2-R172K (IC50=37.9 nM) mutants. TQ05310 inhibits the production of 2-hydroxyglutarate (2-HG) and induces differentiation of cells expressing IDH2-R140Q and IDH2-R172K by inhibiting the enzymatic activity of mutant IDH2. TQ05310 can be used for the study of acute myeloid leukemia[1]. | | IC 50 | IDH2-R140Q: 136.9 nM (IC50); IDH2‐R172K: 37.9 nM (IC50) | | References | [1] Mingzhao Gao, et al. "Pharmacological characterization of TQ 05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants." Cancer science 110.10 (2019): 3306-3314. DOI:10.1111/cas.14152 |
| | TQ05310 Preparation Products And Raw materials |
|